My main areas of interest are the following (relevant publications enumerated below):

  • Comparative effectiveness of cancer-related interventions using claims databases. This work is conducted in collaboration with investigators from the Dana Farber Cancer Insititute in Boston. Funding: NIH P01-CA134294.
    1. Garcia-Albeniz X, Logan RW, Schrag D, Hernán MA. Evaluation of the duplication of staging CT scans for localized colon cancer in Medicare Population. Medical Care. In press.
  • Evaluation of dynamic strategies of treatment in prostate cancer. This work is conducted in collaboration with investigators from the University of California, San Francisco. Funding: NIH P01-CA134294 and CaPSURE Scholarship 2012-2013.
  • Design and analysis of clinical trials. I collaborate in the design and analysis of clinical trials of the GEMCAD group.
    1. Garcia-Albeniz X, Maurel J, Hernán MA. Why post progression survival and post relapse survival are not appropriate measures of efficacy in cancer randomized clinical trials. International Journal of Cancer. In press
  • Clinical and translational research in collaboration with other research centers: Institute for Research in Biomedicine (Barcelona), Hospital Clinic (Barcelona), Hospital del Mar (Barcelona), Queen Mary University (London) and University of Munich.
    1. Urosevic J, Garcia-Albeniz X (co-first author), Planet E, Real S, Céspedes MV, Guiu M, Fernandez E, Bellmunt A, Gawrzak S, Pavlovic M, mangues R, Dolado I, Barriga FM, Nadal C, Kemeny N, Batlle E, Nebreda AR, Gomis RR. Colon cancer cells colonize the lung from established liver metastases through p38 MAPK signalling and PTHLH. Nature Cell Biology. 2014 Jul;16(7):685-94
    2. Garcia-Albeniz X, Gallego R, Hofheinz RD, Fernández-Esparrach G, Ayuso-Colella JR, Bombí JA, Conill C, Cuatrecasas M, Delgado S, Ginés A, Miquel R, Pagés M, Pineda E, Pereira V, Sosa A, Reig O, Victoria I, Feliz L, de Lacy AM, Castells A, Burkholder I, Hochhaus A, Maurel J. Long-term results of rectal cancer treated with chemo-radiation and laparoscopic mesorectal excision and no adjuvant therapy for complete responders. World Journal of Gastroenterology. In press.
    3. Garcia-Albeniz X, Pericay C, Alonso-Espinaco V, Alonso V, Escudero P, Fernández-Martos C, Gallego R, Gascón P, Castellví-Bel, Maurel J. Serum matrilysin correlates with poor survival independently of KRAS and BRAF status in refractory advanced colorectal cancer patients treated with irinotecan plus cetuximab. Tumour Biology. 2011 Apr;32(2);417-24